Compare Boston Beer Company Inc (SAM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Zoetis Inc — how do they compare? Boston Beer Company Inc trades at $183.32 (market cap $1.86B), while Zoetis Inc trades at $73.08 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 16.7× Boston Beer Company Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | ZTS | |
|---|---|---|
Market Cap | $1.86B | $31.14B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $156.76 |
52-Week Low | $161.08 | $71.91 |
Enterprise Value | $1.63B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAM trades at $182.97, up 1.09% on the day, with a bearish technical signal and mixed earnings performance. Recent quarters show misses against estimates, though Q4 2025 beat expectations. The company maintains positive operating cash flow but faces revenue declines and a negative net income margin for 2026. Analyst sentiment is cautious, with a consensus price target of $207.33, while institutional selling and weak demand headlines add pressure.
Outlook is guarded due to volume declines and competitive pressures, offset by a debt-free balance sheet and margin improvements. Risks include sustained demand weakness and execution challenges, but valuation metrics like P/S of 0.99 may attract value investors if turnaround efforts gain traction.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
